Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer

J. N. Ingle, S. J. Green, D. L. Ahmann, H. J. Long, J. H. Edmonson, J. Rubin, M. N. Chang, E. T. Creagan

Research output: Contribution to journalArticle

58 Scopus citations

Abstract

A randomized clinical trial was performed to compare the efficacy of tamoxifen (TAM) alone with that of TAM plus aminoglutethimide (AG) and hydrocortisone (HC). Patients failing TAM could receive AG and HC. Objective responses to therapy were seen in 21 of 49 TAM patients (43%) and 25 of 51 TAM, AG and HC patients (49%). Time to disease progression and survival distributions were not significantly different between the treatment arms. Toxicity was greater for patients treated with TAM, AG, and HC and the trial was discontinued early for this reason. Twenty-four patients received AG and HC after TAM therapy and three (12%) achieved a response. We conclude that the combination of TAM, AG, and HC is not recommended over TAM alone because toxicity appears to outweigh any potential therapeutic advantage.

Original languageEnglish (US)
Pages (from-to)958-964
Number of pages7
JournalJournal of Clinical Oncology
Volume4
Issue number6
DOIs
StatePublished - Jan 1 1986

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Ingle, J. N., Green, S. J., Ahmann, D. L., Long, H. J., Edmonson, J. H., Rubin, J., Chang, M. N., & Creagan, E. T. (1986). Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. Journal of Clinical Oncology, 4(6), 958-964. https://doi.org/10.1200/JCO.1986.4.6.958